A Phase 2 interventional study of Inactivated influenza vaccine (IIV) at baseline and COVID-19 Vaccines at a 3-month interval in COVID 19, Influenza and Rheumatoid Arthritis (RA), sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in COVID-19 by McGill University Health Centre/Research Institute of the McGill University Health Centre — 2 open to participants now, 2 under way, none of them phase 3. COVID-19 · McGill University Health Centre/Research Institute of the McGill University Health Centre.
Among the 12 studies in COVID-19 by McGill University Health Centre/Research Institute of the McGill University Health Centre, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 2, and was the 12th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →2 of the 12 studies in COVID-19 by McGill University Health Centre/Research Institute of the McGill University Health Centre are open now, in 2 countries. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in South Africa
Ages 18+
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 4
First in 2020; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 660 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 132 across the 11 interventional studies, 267 across the 1 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
McGill University Health Centre/Research Institute of the McGill University Health Centre is the lead sponsor of 422 studies on the registry; 106 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in COVID-19 by McGill University Health Centre/Research Institute of the McGill University Health Centre, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with immunocompromising conditions (PLIC).
The main questions it aims to answer are:
Researchers will compare (1) COVID-19 and Influenza vaccines administered at Day 0 + COVID-19 Booster at a 3-month interval, (2) COVID-19 vaccine administered at Day 0 and Influenza vaccine administered at Day 28 + COVID-19 Booster at a 3-month interval, (3) COVID-19 and Influenza vaccines administered at Day 0 + COVID-19 Booster at a 6-month interval, and (4) COVID-19 vaccine administered at Day 0 and Influenza vaccine administered at Day 28 + COVID-19 Booster at a 6-month interval to see if median neutralization capacity of patient sera is non-inferior in the co- vs. sequential administration arms at 1-month after the initial COVID-19 booster and superior in the 3-month interval arms vs. the 6-month interval arms at 12 months after the initial COVID-19 booster. These outcomes will also be compared at 2-months for question 1 and 6-months for question 2.
People living with immunocompromising conditions who take part in the trial will have blood samples drawn to verify immune response, be monitored for changes in clinical events and therapies, and complete questionnaires to verify adverse effects, quality of life and economic impact.
Background:
People living with immunocompromising conditions (PLIC) are more susceptible to complications related to respiratory infections. According to Statistics Canada data, in 2020 approximately 14% of Canadians aged 15 years or older suffered from a compromised immune system. PLIC (e.g., solid organ transplant (SOT) recipients, people living with human immunodeficiency viruses (PLWH), inflammatory bowel disease (IBD), or systemic autoimmune rheumatic diseases (RD) are at risk for experiencing a wide range of respiratory infections. A recent North American study assessed the socioeconomic burden associated with immunocompromising conditions. MarketScan datasets from 2017-2021 showed that PLIC accounted for 32% of hospitalizations for acute respiratory infections (representing a 5-8-fold higher risk than in non-immunocompromised hosts).
PLIC are at elevated risk of severe infection and death from COVID-19 increasing burden to patients and healthcare systems. Often including members of diverse ethnocultural origin, PLIC have also been among the most significantly affected by the COVID-19 pandemic. Vaccination is the most effective way to reduce the severity respiratory disease and infection-associated complications in the general population. Yet, suboptimal immune status results in a higher risk for COVID-19-related hospitalization (up to 13-fold) and death (up to 19-fold) compared with the general population in many PLIC, with substantial implications for healthcare burden and costs, despite PLIC comprising but a minority of the overall population.
Immunogenicity and protection from severe disease can be improved in PLIC with COVID-19 booster doses. A systematic review by the COVID-19 evidence network found that PLIC were more susceptible to severe infections and hospitalizations with emerging variants when compared with the general public. This was attributed to immunomodulatory agents (e.g., calcineurin inhibitors, antimetabolites, steroids, cytotoxic therapy, biological response modifiers) impairing the formation of memory T cells, decreasing cellular-mediated immune responses, and limiting capacity to seroconvert and sustain protective immune memory responses. For example, a meta-analysis in SOT found seroconversion and cellular response rates of 39.2% (95% confidence interval [CI], 33.3%-45.3%) and 41.6% (95% CI, 30.0%-53.6%), respectively, after the primary series in solid organ transplant (SOT).
As the pandemic progressed, it was observed that three or four doses of COVID-19 vaccines increased immunogenicity and protected against severe disease requiring hospitalization, with antibody response being most pronounced in the presence of hybrid immunity, arising when SARS-CoV-2 infection was paired with multiple vaccinations. Importantly, decreased immunogenicity has been observed in PLIC in relation to other vaccines, such as the Inactivated Influenza Vaccine (IIV), warranting high-dose (HD) IIV administration to accomplish seroconversion.
Rationale:
The increased risk of COVID-19 and influenza, alongside adverse outcomes of respiratory infections in PLIC and the variability in vaccine responses highlight the need for optimizing immunogenicity and elucidating the mechanisms underlying blunted and/or less durable vaccine responses in PLIC.
Correlates of protective humoral immunity and COVID-19 disease severity. Antigen-binding antibodies, as well as neutralizing antibodies, have been proposed as independent correlates of protection from SARS-CoV-2 infections. The WHO expert committee consensus defined anti-SARS-CoV-2-S1-Receptor-Binding Domain IgG of BAU/mL as low concentrations, 200-300 BAU/mL as mid-range concentrations, and 700-800 BAU/mL as high concentrations. PLIC demonstrated a reduced capacity to mount protective antibody responses. Yet, additional doses resulted in higher antibody concentrations. A recent analysis by De Serres and team demonstrated antibody levels in the range of 700-1200 BAU/ml conferred protection as measured by a surrogate virus neutralization test (sVNT) threshold of 30% against Omicron. Taken together, this body of evidence suggests that neutralizing or binding anti-S could serve as correlates for protection. Importantly, humoral correlates of protection need to also be evaluated for emerging viral variants especially those which have acquired immune-evasion properties. Moreover, in addition to humoral immunity, spike-specific CD4+ and CD8+ T cells are also critical for vaccine-induced protection and are active contributors to global correlates of protection in many individuals.
Correlates of protective cellular immunity. The identification of correlates of cellular immunity capable of informing clinical care has been hampered by a paucity of rapid antigen-specific cellular immunity assays alongside increased costs and time demands. Activation-induced marker (AIM) assays, wherein antigen-specific T cell subsets are enumerated in peripheral blood mononuclear cells (PBMC) identified by their upregulation of AIM (e.g., CD40L, 4-1BB, CD69), are effective at quantifying virus antigen-reactive T cells. However, the rarity of these cells seldom conveys the quality and functional fate of antigen-specific T cell subsets contributing to the global cellular response. Whether AIM phenotypes could be implemented as rapid assays of cellular immunity and exploited towards clinical decision-making, warrants further study.
The trial will provide evidence to guide health policy in a highly diverse and vulnerable subpopulations of PLIC. More specifically, the trial will inform the preferred vaccine schedule for COVID-19 and IIV in these patients, potentially improving upon vaccine acceptance, adherence, and protection, eventually improving burden to patients, caretakers, and the health care system.
Primary Objective(s):
To assess whether co-administration of seasonal inactivated influenza vaccine (IIV) with the most up-to-date recommended COVID-19 booster dose is non-inferior in inducing a 1-month peak protective humoral response against COVID-19, compared to a strategy of sequential administration of COVID-19 booster dose followed by seasonal IIV given one month later
It is hypothesized that the co-administration strategy will be non-inferior to the sequential strategy in inducing a peak 1-month SARS-CoV-2-specific neutralizing antibody response in PLIC. It will also be less costly, with no increase in adverse effects, and no detrimental effect on response to seasonal IIV as measured by hemagglutination inhibition.
It is hypothesized that the 3-month booster strategy will be superior to the 6-month strategy in inducing a SARS-CoV-2--specific neutralizing antibody response that is sustained for 12 months without increasing adverse effects or disease-specific complications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- All participants must meet ALL the following inclusion criteria: i. Adults (≥18 years) ii. Received the primary mRNA COVID-19 vaccine series (i.e., ≥3 doses) iii. Have at least one of the following immunocompromising conditions:
a) Received a solid organ transplant (SOT) ≥3-months ago, and treated with a conventional maintenance regimen; b) People living with (PLWH) receiving ART for ≥6 months who meet at least one of the following conditions: i) AIDS-defining illness in the last 6 months, ii) TB diagnosis in the last 6-months, iii) CD4\<200 cells/µL in the last 6 months, iv) CD4%\<15% in the last 6 months, or v) absence of HIV viral suppression in the last 6 months; c) Inflammatory bowel disease (IBD) treated with a conventional or biologic immunosuppressive agent for ≥3 months; d) Rheumatoid arthritis or systemic lupus erythematosus (herein referred to as rheumatological disease (RD)) treated with a conventional or biologic immunosuppressive agent for ≥3 months.
Exclusion Criteria:
Potential participants who meet ANY of the following criteria will be excluded:
i. Received any of the following:
<!-- -->
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Covid-19 booster every 3 months and Inactivated influenza vaccine (IIV) at baseline
Biological: Inactivated influenza vaccine (IIV) at baseline · Biological: COVID-19 Vaccines at a 3-month interval
Covid-19 booster every 3 months and IIV at 1 month
Biological: COVID-19 Vaccines at a 3-month interval · Biological: Inactivated influenza vaccine at Month 1
Covid-19 booster every 6 months and IIV at baseline
Biological: Inactivated influenza vaccine (IIV) at baseline · Biological: COVID-19 Vaccines at a 6-month interval
Covid-19 booster every 6 months and IIV at 1 month
Biological: Inactivated influenza vaccine at Month 1 · Biological: COVID-19 Vaccines at a 6-month interval
National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age at baseline
Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 3-month interval
National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age 1-month following initial COVID-19 booster
Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 6-month interval
Median neutralization capacity against prevalent SARS-CoV-2 variant
Median neutralization capacity of patient sera/plasma from each group, as measured by half maximal inhibitory dilution (ID50) against the prevalent SARS-CoV-2 variant circulating at time of measurement. For objective 1, this outcome will be compared between the co- vs. sequential administration arms at 1-month (T1) after the COVID-19 booster (peak humoral response). This outcome will also be compared at 2-months (T2). For objective 2, this outcome will be compared 12-months (T12) after the first COVID-19 booster between participants who have received COVID-19 boosters at 0, 3, 6 and 9 months (3-month interval arm) vs. those who received COVID-19 booster doses at 0 and 6-months (6-month interval arm). This outcome will also be compared at 6-months (T6).
Time frame: At 1-month and 2-months following the initial COVID-19 booster dose for primary objective 1 and at 12-months and 6-months following initial COVID-19 booster dose for primary objective 2
Median neutralization capacity against ancestral and SARS-CoV-2 variant in vaccine
D50 against the SARS-CoV-2 variant included in the vaccine with measurements against the ancestral variant serving as a reference
Time frame: For primary objective 1, at 1-month and 2-months after the COVID-19 booster. For primary objective 2, at 6 and 12 months
Anti-Spike and anti-Nucleocapsid concentrations
Concentration of anti-Spike (response to vaccines) and anti-Nucleocapsid (SARS-CoV-2 infection)
Time frame: Baseline, 1, 2, 4, 6, 7, 10, and 12 months after the first study COVID-19 booster
IgA, and IgM antibody concentration
IgA, and IgM antibody concentration against SARS-CoV-2 and IgG1 to 4 subtypes (in a subset of participants)
Time frame: Baseline, 1, 2, 4, 6, 7, 10, and 12 months after the first study COVID-19 booster
Hemagglutination inhibition (HI) response
Hemagglutination inhibition (HI) response for each influenza strain in the vaccine
Time frame: 1 month after IIV
T-cell responses to SARS-CoV-2 and cytokines assays
T-cell responses to SARS-CoV-2 and cytokine assays (in a subset of participants)
Time frame: Baseline, 1, 2, 4, 6, 7, 10, and 12 months after the first study COVID-19 booster
Repeated measures of ID50
Repeated measures of ID50 against the prevalent, included in the vaccine, and ancestral SARS-CoV-2 variants
Time frame: Baseline, 1- and 2-months for objective 1; 4-, 7-, and 10-months for objective 2
Adverse reactions to the vaccines
Adverse reactions to the vaccines will be verified by monitoring participants for a period of 30 mins following vaccine administration. Also, self-reported adverse events (Reactogenicity) and their severity will be recorded by patients using a diary for a period of 1-week following each vaccine administration.
Time frame: Following COVID-19 booster and/or IIV at baseline, 1, 3, 6 and 9-months
Evidence of immune activation
Evidence of immune activation (e.g., rheumatological or inflammatory bowel disease flares, allograft rejection, or development of donor-specific antibodies)
Time frame: Quarterly (at baseline, 3, 6, 9, and 12-months)
SARS-CoV-2 infections
Evidence of SARS-CoV-2 infections
Time frame: Every visit (at baseline, 1, 2, 3, 4, 6, 7, 9, 10, and 12-months)
Influenza infections
Evidence of Influenza infections
Time frame: Every visit (at baseline, 1, 2, 3, 4, 6, 7, 9, 10, and 12-months)
Emergency room visits
Documented emergency room visits
Time frame: Every visit (at baseline, 1, 2, 3, 4, 6, 7, 9, 10, and 12-months)
Hospitalizations
Documented hospitalizations
Time frame: Every visit (at baseline, 1, 2, 3, 4, 6, 7, 9, 10, and 12-months)
Death
Documented deaths
Time frame: Every visit (at baseline, 1, 2, 3, 4, 6, 7, 9, 10, and 12-months)
Not enrolling at this site.
Plan to share: Yes
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Jan 2028, 38 months after the start.
Of 359 non-industry phase 2 interventional studies under COVID-19, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 38 months is above that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Mar 2027 → Jan 2028 and completion Mar 2027 → Mar 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
McGill University Health Centre/Research Institute of the McGill University Health Centre →